Announcements
- PHAXIAM Therapeutics annonce le recrutement du premier patient dans l’étude de phase 1 dans l’endocardite infectieuse causée par le Staphylococcus aureus
- PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
- Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 mars 2024
- PHAXIAM Therapeutics annonce le dépôt de son Document d’Enregistrement Universel (URD) 2023
- PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
- PHAXIAM Announces 2023 Full-Year Results and Provides Business Update
- PHAXIAM Therapeutics publie ses résultats annuels 2023 et fait le point sur ses activités
- PHAXIAM Therapeutics annonce la réalisation du retrait volontaire de ses « American Depository Shares » du Nasdaq Stock Market
- PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
More ▼
Key statistics
As of last trade Phaxiam Therapeutics SA (0QSS:LSE) traded at 2.92, 3.71% above its 52-week low of 2.82, set on Feb 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 3.44 |
Offer | -- |
Previous close | 2.92 |
Average volume | 70.00 |
---|---|
Shares outstanding | 6.08m |
Free float | 5.60m |
P/E (TTM) | -- |
Market cap | 17.74m EUR |
EPS (TTM) | -5.56 EUR |
Data delayed at least 20 minutes, as of Apr 16 2024 17:52 BST.
More ▼